Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

A $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry Shift

Today 8:45 EST

EQNX::TICKER_START (OTCQB:AIRDF),(CSE:AIDR),(NYSE:TDOC),(NYSE:AMWL),(NYSE:HIMS),(NYSE:DOCS) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Why Hims & Hers Health (HIMS) shares are getting obliterated today

November 10, 2026

What happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 18.5% in the afternoon session after the company reported its financial resul...

Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.

Hims & Hers: 3 Key Takeaways for Long-Term Investors ↗

November 10, 2026

Via The Motley Fool

Topics Earnings

Stock Market Today: Nvidia Board Opens Probe Into Jensen Huang as Wall Street Licks Its AI Wounds ↗

November 10, 2026

Via Chartmill

Topics Artificial Intelligence

Hims & Hers (HIMS) Q3 2026 Earnings Call Transcript ↗

November 10, 2026

International expansion offset a U.S. subscriber slowdown in the quarter.

Via The Motley Fool

Topics Earnings

HIMS Q3 2026 deep dive: cautious marketing spend and product launches shape guidance

November 10, 2026

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with sales up 48.6% year on year to $890.4 million. On t...

Hims & Hers Health (NYSE:HIMS) reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and...

What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call ↗

November 10, 2026

Via MarketBeat

Topics Earnings

Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations

November 09, 2026

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with revenue up 48.6% year on year to $890.4 million. On...

Dr. Andrew Huberman Joins Hims & Hers Board of Directors

November 09, 2026

From Hims & Hers

Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

November 09, 2026

From Hims & Hers

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday after market close. Here’s what you need to know. Hims & Hers Health...

Hims & Hers Health earnings: what to look for from HIMS

November 07, 2026

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027? ↗

Topics Artificial Intelligence

November 06, 2026

Both are disruptors, but one of these growth stocks stands out over the other.

Via The Motley Fool

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

November 06, 2026

From Hims & Hers

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market

Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch ↗

November 05, 2026

Via MarketBeat

November 05, 2026

New HHS Direction Creates Potential Opportunities for Peptide Manufacturers, Biotech Companies, and Healthcare Innovators

From FN Media

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market

November 05, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NASDAQ:MBX),(NASDAQ:KLRA),(NASDAQ:ALT),(NYSE:HIMS) EQNX::TICKER_END

Via FinancialNewsMedia

Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most

November 05, 2026

From Hims & Hers

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Hims & Hers Health, RadNet, and Henry Schein shares are soaring, what you need to know

November 04, 2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Topics Economy

November 02, 2026

From Faruqi & Faruqi, LLP

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

November 02, 2026

From Schall, Brown & Schwartz LLP

HIMS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urges Hims & Hers Health, Inc. Investors to Contact the Firm Before November 2nd

October 31, 2026

From Bragar Eagel & Squire

Hims & Hers Health 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

October 30, 2026

From Kahn Swick & Foti, LLC

Kaplan Fox Urges Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm Before the Securities Class Action Deadline on November 2, 2026

October 30, 2026

From Kaplan Fox & Kilsheimer, LLP

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

October 29, 2026

From SkyMedia, LLC

Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Learn About the Securities Class Action Ahead of the November 2, 2026 Deadline

October 29, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

October 29, 2026

From Schall, Brown & Schwartz LLP

Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments.

The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth

October 29, 2026

From FN Media

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END

The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth

October 29, 2026

Via FinancialNewsMedia

HIMS Deadline in 5 Days: Hims & Hers Health, Inc. Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline - Contact Kessler Topaz Meltzer & Check, LLP

October 28, 2026

From Kessler Topaz Meltzer & Check, LLP